HI
CLVS

HBK Investments’s Clovis Oncology, Inc. CLVS Stock Holding History

HBK Investments’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-66,873
Closed -$3.53M – 1206
2018
Q1 		$3.53M Sell
66,873
-17,233
-20% -$1.01M 0.02% 349
2017
Q4 		$5.72M Buy
84,106
+57,442
+215% +$4.02M 0.04% 241
2017
Q3 		$2.2M Sell
26,664
-98,742
-79% -$7.83M 0.01% 424
2017
Q2 		$11.7M Buy
125,406
+3,507
+3% +$215K 0.07% 139
2017
Q1 		$7.76M Buy
+121,899
New +$7.41M 0.06% 181
2015
Q4 		– Sell
-21,400
Closed -$1.97M – 1161
2015
Q3 		$1.97M Buy
+21,400
New +$1.85M 0.02% 424
2014
Q2 		– Sell
-6,100
Closed -$423K – 1074
2014
Q1 		$423K Sell
6,100
-26,600
-81% -$1.95M 0.01% 700
2013
Q4 		$1.97M Buy
+32,700
New +$1.78M 0.04% 300

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

HBK Investments's CLVS Position: Q2 2018 in Review

HBK Investments sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 66,873 shares — an estimated $3.53M sold.

HBK Investments first reported a position in CLVS in Q4 2013 and held it in 8 quarters. The position peaked at $11.7M in Q2 2017. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • HBK Investments reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • HBK Investments sold 66,873 Clovis Oncology, Inc. shares in Q2 2018, an estimated $3.53M.
  • HBK Investments first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 8 quarters.
  • HBK Investments's Clovis Oncology, Inc. position peaked at $11.7M in Q2 2017.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on HBK Investments's 13F filing for Q2 2018, filed 14 Aug 2018.